ES2717757T3 - Compuestos - Google Patents
Compuestos Download PDFInfo
- Publication number
- ES2717757T3 ES2717757T3 ES15743645T ES15743645T ES2717757T3 ES 2717757 T3 ES2717757 T3 ES 2717757T3 ES 15743645 T ES15743645 T ES 15743645T ES 15743645 T ES15743645 T ES 15743645T ES 2717757 T3 ES2717757 T3 ES 2717757T3
- Authority
- ES
- Spain
- Prior art keywords
- pyrrolo
- ethoxy
- methanone
- amino
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C[C@@](COCC1)N1C(c1cc(OC)c(*)cc1)=O Chemical compound C[C@@](COCC1)N1C(c1cc(OC)c(*)cc1)=O 0.000 description 4
- ZGJVSCMCFKGKEW-UHFFFAOYSA-N CCOc1c(c(C(F)(F)F)c[nH]2)c2nc(Nc(ccc(C(N2CCOCC2)=O)c2)c2OC)n1 Chemical compound CCOc1c(c(C(F)(F)F)c[nH]2)c2nc(Nc(ccc(C(N2CCOCC2)=O)c2)c2OC)n1 ZGJVSCMCFKGKEW-UHFFFAOYSA-N 0.000 description 1
- FJNNNKKFKHEAET-UHFFFAOYSA-N CCOc1c(cc[nH]2)c2nc(Nc(ccc(C(N2CCC(COC)CC2)=O)c2)c2OC)n1 Chemical compound CCOc1c(cc[nH]2)c2nc(Nc(ccc(C(N2CCC(COC)CC2)=O)c2)c2OC)n1 FJNNNKKFKHEAET-UHFFFAOYSA-N 0.000 description 1
- MYLZMKPYMYDDHN-UHFFFAOYSA-N CCOc1c(cc[nH]2)c2nc(Nc(ccc(C(N2CCN(C)CC2)=O)c2)c2F)n1 Chemical compound CCOc1c(cc[nH]2)c2nc(Nc(ccc(C(N2CCN(C)CC2)=O)c2)c2F)n1 MYLZMKPYMYDDHN-UHFFFAOYSA-N 0.000 description 1
- DNLMWWLLGMTQII-UHFFFAOYSA-N CCOc1nc(Cl)nc2c1cn[nH]2 Chemical compound CCOc1nc(Cl)nc2c1cn[nH]2 DNLMWWLLGMTQII-UHFFFAOYSA-N 0.000 description 1
- KPSBLSBABRIUJP-UHFFFAOYSA-N CCOc1ncnc2c1cc[nH]2 Chemical compound CCOc1ncnc2c1cc[nH]2 KPSBLSBABRIUJP-UHFFFAOYSA-N 0.000 description 1
- IXUCYGQTKDSONM-UHFFFAOYSA-N COC(c(cc1)cc(OC(F)F)c1[N+]([O-])=O)=O Chemical compound COC(c(cc1)cc(OC(F)F)c1[N+]([O-])=O)=O IXUCYGQTKDSONM-UHFFFAOYSA-N 0.000 description 1
- KMWMHGDGKNFOMV-UHFFFAOYSA-N [O-][N+](c(ccc(C(O)=O)c1Cl)c1O)=O Chemical compound [O-][N+](c(ccc(C(O)=O)c1Cl)c1O)=O KMWMHGDGKNFOMV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014000140 | 2014-01-29 | ||
| PCT/CN2015/000054 WO2015113451A1 (en) | 2014-01-29 | 2015-01-28 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2717757T3 true ES2717757T3 (es) | 2019-06-25 |
Family
ID=53756223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15743645T Active ES2717757T3 (es) | 2014-01-29 | 2015-01-28 | Compuestos |
Country Status (9)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20160348A (es) | 2014-01-29 | 2017-04-28 | Glaxosmithline Intellectual Property Dev Ltd | Compuestos |
| EP3256475A4 (en) * | 2015-02-13 | 2019-02-13 | Dana-Farber Cancer Institute, Inc. | LRRK2 INHIBITORS AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| WO2017106771A1 (en) | 2015-12-16 | 2017-06-22 | Southern Research Institute | Pyrrolopyrimidine compounds, use as inhibitors of the kinase lrrk2, and methods for preparation thereof |
| EP3573980A4 (en) * | 2017-01-25 | 2020-08-19 | GlaxoSmithKline Intellectual Property Management Limited | LINKS |
| BR112019015314A2 (pt) | 2017-01-25 | 2020-05-19 | Glaxosmithkline Ip Dev Ltd | compostos para inibir a atividade da quinase lrrk2 |
| EP3587422A4 (en) * | 2017-02-22 | 2020-05-06 | Daegu-Gyeongbuk Medical Innovation Foundation | PYRROLO-PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF A PROTEIN KINASE-RELATED DISEASE |
| KR101896568B1 (ko) * | 2017-03-23 | 2018-09-10 | 재단법인 대구경북첨단의료산업진흥재단 | 피롤로-피리딘 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 |
| CA3168222A1 (en) * | 2019-01-18 | 2020-07-23 | Voronoi Co., Ltd. | Pyrrolopyrimidine derivatives and pharmaceutical composition for preventing or treating protein kinase-related disease comprising the same as an active ingredient |
| CA3168211A1 (en) * | 2019-01-18 | 2020-07-23 | Voronoi Co., Ltd. | Pyrrolopyridine derivative and use thereof for preventing or treating protein kinase related disease |
| CZ308800B6 (cs) * | 2019-02-12 | 2021-05-26 | Univerzita Palackého v Olomouci | Heterocyklické dusíkaté deriváty purinu, farmaceutické přípravky obsahující tyto deriváty a jejich použití při neuroprotekci |
| US20220204515A1 (en) * | 2019-05-16 | 2022-06-30 | Dana-Farber Cancer Institute, Inc. | Pyrrolopyrimidine inhibitors of wild-type and mutant forms of lrrk2 |
| CN111205216B (zh) * | 2020-03-11 | 2022-03-29 | 连云港恒运药业有限公司 | 一种制备沙格列汀的方法 |
| AU2021371697A1 (en) * | 2020-10-29 | 2023-06-22 | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | Substituted diarylamine compound, pharmaceutical composition thereof, preparation method therefor, and use thereof |
| WO2022155419A1 (en) * | 2021-01-15 | 2022-07-21 | ESCAPE Bio, Inc. | Indazoles and azaindazoles as lrrk2 inhibitors |
| CA3214360A1 (en) | 2021-03-23 | 2022-09-29 | Halia Therapeutics, Inc. | Pyrimidine derivatives useful as lrrk2 kinase inhibitors |
| WO2023073013A1 (en) | 2021-10-27 | 2023-05-04 | H. Lundbeck A/S | Lrrk2 inhibitors |
| CN115108991B (zh) * | 2022-06-30 | 2023-05-05 | 南京理工大学 | 一种硝仿基吡唑起爆药及其制备方法 |
| WO2024056775A1 (en) | 2022-09-15 | 2024-03-21 | H. Lundbeck A/S | Macrocyclic leucine-rich repeat kinase 2 (lrrk2) inhibitors |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004274403A1 (en) | 2003-09-03 | 2005-03-31 | Aventis Pharmaceuticals Inc. | 5-aryl-Pyrazolo(4,3-d)pyrimidines, pyridines, and pyrazines and related compounds |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| US7855205B2 (en) | 2004-10-29 | 2010-12-21 | Janssen Pharmaceutica Nv | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| EP1948658A1 (en) * | 2005-10-13 | 2008-07-30 | Glaxo Group Limited | Pyrrolopyrimidine derivatives as syk inhibitors |
| CA2651072A1 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| WO2009036066A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Vegfr inhibitors containing a zinc binding moiety |
| US9315449B2 (en) | 2008-05-15 | 2016-04-19 | Duke University | Substituted pyrazoles as heat shock transcription factor activators |
| US8158636B2 (en) | 2008-05-19 | 2012-04-17 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| US20090325964A1 (en) | 2008-05-23 | 2009-12-31 | Wyeth | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression |
| CN102482277B (zh) * | 2009-05-05 | 2017-09-19 | 达纳-法伯癌症研究所有限公司 | 表皮生长因子受体抑制剂及治疗障碍的方法 |
| CA2775753A1 (en) | 2009-09-29 | 2011-04-07 | Paula Louise Nichols | Lrrk2 kinase inhibitors |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| PL2576541T3 (pl) * | 2010-06-04 | 2016-10-31 | Pochodne aminopirymidyny jako modulatory lrrk2 | |
| WO2012009258A2 (en) | 2010-07-13 | 2012-01-19 | Edward Roberts | Peptidomimetic galanin receptor modulators |
| WO2012045195A1 (en) * | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases |
| EP2637669A4 (en) | 2010-11-10 | 2014-04-02 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and their use |
| LT3124483T (lt) | 2010-11-10 | 2019-09-25 | Genentech, Inc. | Pirazolo aminopirimidino dariniai, kaip lrrk2 moduliatoriai |
| CA2818903C (en) | 2010-12-14 | 2021-03-23 | Electrophoretics Limited | 5-(1,3-benzoxazol-2-yl)-4-(pyridin-4-yl)pyrimidin-2-amine and its use as a casein kinase 1delta inhibitor |
| TWI606049B (zh) * | 2011-04-21 | 2017-11-21 | 原真股份有限公司 | 新穎激酶抑制劑 |
| KR20140059246A (ko) | 2011-09-22 | 2014-05-15 | 화이자 인코포레이티드 | 피롤로피리미딘 및 퓨린 유도체 |
| WO2013079496A1 (en) | 2011-11-30 | 2013-06-06 | F. Hoffmann-La Roche Ag | Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (pet) imaging for lrrk2 |
| GB201204985D0 (en) * | 2012-03-21 | 2012-05-02 | Genentech Inc | Compounds |
| CN106279202A (zh) | 2012-05-03 | 2017-01-04 | 霍夫曼-拉罗奇有限公司 | 作为lrrk2调节剂用于治疗帕金森病的吡唑氨基嘧啶衍生物 |
| EP2844652B1 (en) | 2012-05-03 | 2019-03-13 | Genentech, Inc. | Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
| AP3902A (en) * | 2012-06-29 | 2016-11-17 | Pfizer | Novel 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors |
| CR20160348A (es) | 2014-01-29 | 2017-04-28 | Glaxosmithline Intellectual Property Dev Ltd | Compuestos |
-
2015
- 2015-01-28 CA CA2937430A patent/CA2937430A1/en not_active Abandoned
- 2015-01-28 CN CN201580006294.1A patent/CN105980388B/zh not_active Expired - Fee Related
- 2015-01-28 ES ES15743645T patent/ES2717757T3/es active Active
- 2015-01-28 EP EP15743645.2A patent/EP3099694B1/en active Active
- 2015-01-28 AU AU2015210554A patent/AU2015210554A1/en not_active Abandoned
- 2015-01-28 WO PCT/CN2015/000054 patent/WO2015113451A1/en active Application Filing
- 2015-01-28 US US15/114,857 patent/US9815841B2/en not_active Expired - Fee Related
- 2015-01-28 JP JP2016549113A patent/JP6474826B2/ja not_active Expired - Fee Related
- 2015-01-28 RU RU2016134751A patent/RU2016134751A/ru not_active Application Discontinuation
-
2018
- 2018-01-12 AU AU2018200271A patent/AU2018200271A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP6474826B2 (ja) | 2019-02-27 |
| CN105980388B (zh) | 2018-01-16 |
| EP3099694A4 (en) | 2017-06-14 |
| AU2018200271A1 (en) | 2018-02-01 |
| WO2015113451A1 (en) | 2015-08-06 |
| US9815841B2 (en) | 2017-11-14 |
| RU2016134751A (ru) | 2018-03-02 |
| AU2015210554A1 (en) | 2016-07-07 |
| CA2937430A1 (en) | 2015-08-06 |
| JP2017504635A (ja) | 2017-02-09 |
| CN105980388A (zh) | 2016-09-28 |
| EP3099694A1 (en) | 2016-12-07 |
| US20170022204A1 (en) | 2017-01-26 |
| EP3099694B1 (en) | 2019-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2717757T3 (es) | Compuestos | |
| ES2855135T3 (es) | Amidas heterocíclicas como inhibidores de quinasa | |
| JP6745824B2 (ja) | 複素環化合物 | |
| EP2883875B1 (en) | N2,n4-bis(4-(piperazine-1-yl)phenyl)pirimidine-2,4-diamine derivative or pharmaceutically acceptable salt thereof, and composition containing the same as active ingredient for preventing or treating cancer | |
| JP2020526543A (ja) | ロイシンリッチリピートキナーゼ２の阻害剤 | |
| TW200835481A (en) | Imidazotriazines and imidazopyrimidines as kinase inhibitors | |
| WO2018137607A1 (en) | Compounds | |
| JP6698633B2 (ja) | 複素環化合物 | |
| BR112015017759B1 (pt) | Compostos inibidores de fosfolipase a2 associada à lipoproteína (lp-pla2) à base de 2,3-dihidroimidazol[1,2-c]pirimidin5(1h)-ona, e composição farmacêutica compreendendo tais compostos | |
| CN110678467A (zh) | 治疗化合物和组合物及其使用方法 | |
| BR112019015273A2 (pt) | compostos | |
| KR20160106623A (ko) | 화합물 | |
| BR112019015278A2 (pt) | compostos | |
| US20140155375A1 (en) | Novel compounds | |
| US11034696B2 (en) | Compounds for inhibiting LRRK2 kinase activity | |
| US20190389850A1 (en) | Compounds |